https://www.mri.theclinics.com/article/S1064-9689(09)00137-8/pdf

Imaging of lymphoma of the musculoskeletal system.

https://doi.org/10.1016/j.ijscr.2022.107267

Acetabular reconstruction with total hip replacement and femoral head autograft following pelvic resection of malignant bone tumour: A case report

Background: Hodgkin’s and non-Hodgkin’s lymphoma commonly occur in patients in their middle years and are more frequent in males than in females. The cause of these entities is unknown, although infectious, immunologic and genetic origins have been postulated. Both diseases, and in particular, Hodgkin’s lymphoma, are rarely seen in the skeletal system and are generally thought to have a better prognosis when confined to bone. Methods: The authors have treated 140 patients with Hodgkin’s lymphoma (ten patients) and non-Hodgkin’s lymphoma (130 patients) since 1972 and report the results in this presentation. More males were affected than females and the mean age of the study group was 45 years. The majority of these patients were MusculoSkeletal Tumor Society (MSTS) Stage II and Ann Arbor Stage IE. The principal sites of tumor occurrence were the femur, pelvis, tibia, humerus, spine and shoulder. Most often, treatment consisted of intralesional surgery followed by radiation and chemotherapy and only 12 of the 140 patients had marginal or wide resective surgery. Results: Overall survival for the patients was 68% in the non-Hodgkin’s group (130 patients), but only 50% for those with Hodgkin’s disease (ten patients). In addition, MSTS Stage, date of presentation and anatomic site had a significant effect on survival. Conclusions: Lymphoma principally occurring in bone is a difficult problem, partly because there is a high degree of variation in the presentation and treatment protocols are highly variable and sometimes not effective.

/pdf/lymphoma-of-bone-a-review-of-140-patients-1g5bxlo226.pdf

Lymphoma of bone: a review of 140 patients

The purpose of this brief report is to review a large series of cases of myeloma, a highly malignant tumor.  The disease was first described over 150 years ago, but not named myeloma until 1873. The lesion appears to be caused by the production of plasma cells in the bone marrow occasionally associated with amyloid. Patients present with pain in bones, principally spine, pelvis, ribs, calvarium and long bones. The sedimentation rate is elevated and marrow shows 10% plasma cells and the sedimentation rate is always elevated.  There is no identified genetic cause and the disease is not familial. The disease has a highly malignant potential. We treated 181 mature adult patients with tumor in multiple sites. 63% were dead of disease at an average of  4.5 years after diagnosis. The use of some new drugs have been helpful, chiefly lalanlidomide or bortezomib. Radiation appears to be useful for some lesions and bisphosphonates sometimes help support the bone structure. Despite many efforts over the years and the large number of treatment agents introduced, it is apparent that we do not have sufficient ability or knowledge to control this very troublesome disorder.

/pdf/myeloma-a-malignant-disorder-of-bone-and-soft-tissue-18iyg6gh27.pdf

Henry J. Mankin

Papers

Lymphoma of bone: a review of 140 patients

Myeloma: A malignant disorder of bone and soft tissue